Neotrace: A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer.

Authors: Friederike C. Althoff, Fabian Acker, Sebastian Koschade, Sophie Heinzen, Lukas Aguinarte, Maximilian Rost, Hanna Schulte, Gernot Rohde, Melanie Demes, Waldemar Schreiner, Katrin Krause, Viktor Grünwald, Hubert Serve, Thomas Oellerich, Martin Sebastian

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps8120

Source: Full article

---

Abstract

TPS8120